Cargando…

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer

Triple negative breast cancer (TNBC) is an aggressive disease that is difficult to treat and portends a poor prognosis in many patients. Recent efforts to implement immune checkpoint inhibitors into the treatment landscape of TNBC have led to improved outcomes in a subset of patients both in the ear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schreier, Ashley, Zappasodi, Roberta, Serganova, Inna, Brown, Kristy A., Demaria, Sandra, Andreopoulou, Eleni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872136/ https://www.ncbi.nlm.nih.gov/pubmed/36703796 http://dx.doi.org/10.3389/fonc.2022.1061789

Ejemplares similares

Taming Tumor Glycolysis and Potential Implications for Immunotherapy
por: Ganapathy-Kanniappan, Shanmugasundaram
Publicado: (2017)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer
por: Ruan, Yuxia, et al.
Publicado: (2023)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2023)

Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy
por: Xu, Ming, et al.
Publicado: (2022)

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
por: Caputo, Roberta, et al.
Publicado: (2023)

Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer
por: Wang, Xin-Hua, et al.
Publicado: (2022)

Development and validation of an inflammatory response-related signature in triple negative breast cancer for predicting prognosis and immunotherapy
por: Guo, Yangyang, et al.
Publicado: (2023)

Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies
por: Serganova, Inna, et al.
Publicado: (2022)

GDF11 Implications in Cancer Biology and Metabolism. Facts and Controversies
por: Simoni-Nieves, Arturo, et al.
Publicado: (2019)

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
por: He, Qin, et al.
Publicado: (2021)

Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer
por: Jiang, Ke, et al.
Publicado: (2021)

Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications
por: Shan, Jingxuan, et al.
Publicado: (2019)

Combinations of Immunotherapy and Radiation in Cancer Therapy
por: Vatner, Ralph E., et al.
Publicado: (2014)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer
por: Liu, Xinkui, et al.
Publicado: (2021)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Radiotherapy Effects on Anti-Tumor Immunity: Implications for Cancer Treatment
por: Demaria, Sandra, et al.
Publicado: (2013)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model
por: Jallad, Mary-Ann N., et al.
Publicado: (2020)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Regulatory Mechanisms of LncRNAs in Cancer Glycolysis: Facts and Perspectives
por: Huang, Peng, et al.
Publicado: (2021)

Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women
por: Diaz Casas, Sandra, et al.
Publicado: (2019)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Biglycan and reduced glycolysis are associated with breast cancer cell dormancy in the brain
por: Sunderland, Ashley, et al.
Publicado: (2023)

Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
por: Luo, Zhong-Wei, et al.
Publicado: (2020)

Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer
por: Ensenyat-Mendez, Miquel, et al.
Publicado: (2021)

Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
por: Pilones, Karsten A., et al.
Publicado: (2020)

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer
por: Mast, Jesse M., et al.
Publicado: (2018)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_verkg61va0k30brf81a8hab2mq